-
Encouraging Phase II data supports broad therapeutic potential of eftilagimod alpha in non-small cell lung cancer (NSCLC), head & neck squamous cell cancer (HNSCC) and metastatic breast cancer (MBC)
-
Planning and regulatory interactions ongoing with a focus now prioritising 1st line (1L) NSCLC
-
New and important clinical data in 1L NSCLC expected in Q4 2022
-
Continued expansion of efti in additional indications and combinations planned
-
Strong balance sheet provides cash runway into early 2024
SYDNEY, AUSTRALIA – 14 September 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, provides a clinical development update for its first-in-class LAG-3 antigenpresenting cell (APC) activator product candidate, eftilagimod alpha (“efti”).
For more information, download the attached PDF.
Download this document
